Which Documents Need Certified Translation Under EU CTR 536/2014
- 3 days ago
- 5 min read
Five document types have to reach every trial site in that country's official language before an EU ethics committee will clear the study: informed consent forms and patient information sheets, subject-facing recruitment material, ethics-committee and Part II correspondence, investigational medicinal product labelling, and the lay summary of results. Regulation (EU) No 536/2014, the Clinical Trials Regulation, leaves the exact language to each Member State under Article 26, so "which language" is answered site by site, not once for the whole trial.
"Certified" here rarely means a sworn stamp on every page. It means the site-language version was produced under a documented, auditable process, and for anything a patient reads it means back-translation and reconciliation you can show later. ICH E6(R3) Good Clinical Practice, in force across the EU since 23 July 2025, makes the sponsor accountable for that translation process and expects the trail to sit in the trial master file. Get it right and the file is quiet at inspection. Get it wrong and a single leaflet stalls a country.
One date frames all of this. The Clinical Trials Directive transition ended on 31 January 2025, so the Clinical Trials Information System (CTIS) is now the only portal, and a legacy trial that never converted has to start again. There is no slow lane left for a late translation.
1. Informed consent forms and patient information sheets
Article 29 requires informed consent in writing, in a language the subject understands, in plain lay terms. In practice the site's ethics committee, reviewing the Part II dossier, wants the ICF and patient information sheet in the official language of that Member State. A dosing instruction or a risk statement that reads one way in Dutch and another in Polish is the quickest route to a Part II objection. Back-translation and reconciliation are the evidence a reviewer looks for, so a mismatch here doesn't just risk a query, it delays site activation by weeks.
2. Subject-facing recruitment material
Adverts, posters, screening scripts, and social posts all count. They travel in the same Part II dossier, and the ethics committee reads them in the local language. Wording that oversells benefit or softens a risk gets flagged fast, because recruitment copy is where a small translation drift becomes a consent problem. The consequence is a recruitment hold: you cannot approach a single participant in that country until the corrected wording is re-approved.
3. Ethics-committee and Part II submission correspondence
Article 26 hands the language of the dossier to the Member State. Most accept English for the Part I science, the protocol and investigator's brochure, then require the national language for Part II and for responses to requests for information. Miss that and the assessment clock pauses. Under the CTR's fixed timelines a paused clock is not neutral, because every day a translated answer sits unfiled is a day added to a schedule that sponsors and sites have already committed to.
4. Investigational medicinal product labelling
Annex VI sets what an IMP label must carry, and Article 69 leaves the label language to the Member State where the trial runs. This one bites at the pharmacy, not the ethics desk. A kit labelled in the wrong language can't be released to the site, so a labelling gap shows up as blocked stock and a patient who can't be dosed on schedule. Because label text repeats across every participating country, a shared, version-locked term base is what keeps the same warning identical in 12 languages rather than 12 near-misses.
5. The lay summary of trial results
Article 37 and Annex V require a summary written for laypersons, in a language each participating country's public can read, posted to CTIS after the trial ends. It arrives long after the exciting work is done, which is exactly why it slips. A missing or machine-dumped lay summary is a transparency failure recorded against the sponsor, visible in the public CTIS record, and it is the cheapest of these five to get right if you plan the translation into the closeout rather than after it.
How we handle certified trial translation
We at AD VERBUM treat every one of these documents as an audit artifact, not a delivery. Our process runs under ISO 17100, so an independent second linguist revises patient-facing text rather than the original translator signing off alone, and our ISO 13485 medical-device quality system and ISO 27001 information-security controls govern how special-category patient data moves. That last point matters under GDPR Article 9: consent and patient material carry health data, so we keep it on EU-hosted infrastructure with a clear processing basis. The same discipline sits behind our work on multilingual TMF requirements under ICH E6(R3) and the way a single source change cascades across every EU language version.
For each translated document, an inspector following ICH E6(R3) expects to open the trial master file and find:
the translator and reviewer qualification records, showing who worked on each version and why they were competent for it
the back-translation and reconciliation report for patient-facing text, with the resolved discrepancies
a version and change-control log that ties each language version to the approved source
a dated sign-off for every language, so the approval sequence is provable, not asserted
None of that is exotic. It is the certification stack regulated translation now takes for granted, applied to a clinical file instead of a device or a pharma dossier.
Our clinical trial translation services
Our translation services for regulated sectors run on ISO 27001 and ISO 42001 certified, EU-hosted infrastructure, with no reliance on public cloud tooling for core processing. Every project runs through our AI+HUMAN hybrid workflow: we ingest client Translation Memories and Term Bases first, our proprietary LLM-based LangOps System generates output constrained by client terminology on client-tuned open-weight models, and our certified subject-matter experts review for technical accuracy and regulatory compliance. Our QA is aligned to ISO 17100 and ISO 18587, with sector-specific requirements such as CTR 536/2014 site-language rules and ICH E6(R3) documented-process expectations applied where relevant. We serve Life Sciences, Legal, Finance, Defense, and Manufacturing clients across 150+ languages with 3,500+ subject-matter linguists. For teams managing audit-sensitive content, contact us to discuss your security and compliance requirements directly.
FAQ
Does CTR 536/2014 require certified translation of every trial document?
No. Article 26 lets each Member State set the language of the dossier, and most accept English for the Part I scientific documents. Patient-facing material, the informed consent form, patient information sheet, and recruitment copy, must be in the site's official language and produced under a documented, quality-assured process.
Which article governs informed consent language?
Article 29 of Regulation (EU) No 536/2014 requires informed consent in writing, in a language the subject understands, in plain lay terms. The site ethics committee reviews it as part of the Part II assessment.
What happens if an informed consent translation is wrong?
The Part II ethics assessment can reject it, which delays site activation. ICH E6(R3), effective in the EU since 23 July 2025, also expects back-translation and reconciliation evidence in the trial master file, so an undocumented process is itself an inspection finding.
What changed on 31 January 2025?
The Clinical Trials Directive transition period ended. CTIS is now the sole portal for authorisation and registration, and any legacy trial not transitioned before that date is no longer valid and needs a fresh CTR application.
What language must investigational medicinal product labelling use?
Annex VI sets the label content and Article 69 leaves the language to the Member State where the trial takes place. A kit labelled in the wrong language cannot be released to the site pharmacy, so the gap surfaces as blocked stock rather than an ethics query.
How does GDPR apply to translated clinical documents?
Consent forms and patient material are special-category data under GDPR Article 9. The translated version must preserve the lawful-processing basis, and the files should be handled on secure, EU-hosted infrastructure under ISO 27001 rather than passed through public tools.
